<DOC>
	<DOCNO>NCT00354562</DOCNO>
	<brief_summary>To determine efficacy ABT-751 administer combination standard docetaxel subject advance metastatic NSCLC .</brief_summary>
	<brief_title>A Phase 2 Study Evaluating ABT-751 Combination With Taxotere Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Pathologically document NSCLC Locally advance ( Stage III ) metastatic ( Stage IV ) NSCLC Only one prior antitumor treatment regimen noncurative setting ( i.e. , 2ndline therapy ) Only one prior antitumor treatment regimen curative set Progressive disease follow previous antitumor treatment regimen Measurable disease RECIST criterion Brain metastasis must stable wellcontrolled ECOG performance score 02All antitumor therapy discontinue least 3 week prior study entryAll adverse event prior treatment resolve stableAdequate hematologic , renal , hepatic functionFemales must pregnantWilling take adequate measure prevent pregnancyLife expectancy least 3 monthsAble complete Quality Life questionnaireVoluntarily sign informed consent Only one prior antitumor treatment regimen curative set Progressive disease follow previous antitumor treatment regimen Measurable disease RECIST criterion Brain metastasis must stable wellcontrolled ECOG performance score 02 All antitumor therapy discontinue least 3 week prior study entry All adverse event prior treatment resolve stable Adequate hematologic , renal , hepatic function Females must pregnant Willing take adequate measure prevent pregnancy Life expectancy least 3 month Able complete Quality Life questionnaire Voluntarily sign inform consent Greater Grade 1 neurological finding Allergy sulfa medication Previous treatment ABT751 docetaxel Receipt one investigational agent NSCLC Significant weight loss ( &gt; 10 % ) within 6 week study entry Glucose6phosphate dehydrogenase deficiency porphyria Significant systemic disease would adversely affect participation Class 34 New York Heart Association classification status Other cancer except situ carcinoma cervix , basal squamous cell skin cancer , cancer consider adequately treat cured investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>ABT-751</keyword>
	<keyword>docetaxel</keyword>
	<keyword>Taxotere</keyword>
</DOC>